NCT07683065 A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
| NCT ID | NCT07683065 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Plaque Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-07-08 |
| Primary Completion | 2027-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2026-07-08 with a primary completion date of 2027-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
Eligibility Criteria
Inclusion criteria: * Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023. * Patients aged ≥18 years at index date. * Patients with no prior secukinumab exposure in available EMR history. * Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA). * Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC). * Patients with confirmed plaque psoriasis with or without PsA. * Patients with at least one cardiometabolic risk factor. * Patients with a confirmed MASLD diagnosis. * Patients with baseline laboratory data available. Exclusion criteria: * Patients with evidence of MASLD absence. * Patients with malignant liver disease. * Patients with a history of liver transplantation. * Patients with alcohol use disorder. * Patients with other chronic liver diseases. * Patients with diseases or treatments which cause thrombocytopenia. * Patients with decompensated cirrhosis. Other protocol-defined inclusion/exclusion criteria may apply.
Contact & Investigator
Novartis Pharmaceuticals
STUDY DIRECTOR
Novartis Pharmaceuticals
Frequently Asked Questions
Who can join the NCT07683065 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Plaque Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07683065 currently recruiting?
Yes, NCT07683065 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT07683065 trial being conducted?
This trial is being conducted at Badalona, Spain, Barcelona, Spain, Madrid, Spain, Málaga, Spain.
Who is sponsoring the NCT07683065 clinical trial?
NCT07683065 is sponsored by Novartis Pharmaceuticals. The principal investigator is Novartis Pharmaceuticals at Novartis Pharmaceuticals. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.